⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13772656 | 0.82 | HDAC7 (0.40) | — | |
| SCHEMBL211902 | 0.82 | HDAC7 (0.40) | — | |
| SCHEMBL933824 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL21378767 | 0.79 | CA1 (0.44) | — | |
| SCHEMBL16448919 | 0.79 | ADAM17 (0.30) | — | |
| SCHEMBL26319558 | 0.77 | ALDH1A1 (0.37) | — | |
| SCHEMBL18391325 | 0.77 | ADAM17 (0.42) | — | |
| SCHEMBL20305013 | 0.77 | ZDHHC7 (0.46) | — | |
| SCHEMBL21318802 | 0.76 | LMNA (0.32) | — | |
| SCHEMBL8161232 | 0.76 | HDAC2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4262788-A1 | UREA OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022132696-A1 | UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-06-23 | — | — | WO | disclosed |
| EP-2771009-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corp. (US) | 2014-09-03 | — | — | EP | disclosed |
| EP-2750504-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013063385-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-05-02 | — | — | WO | disclosed |
| WO-2013033258-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-8221771-B2 | Formulations containing an immune response modifier | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-07-17 | — | — | US | disclosed |
| EP-1966146-A1 | 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS | Solvay Pharmaceuticals B.V. (NL) | 2008-09-10 | — | — | EP | disclosed |
| EP-1924264-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| US-20070292456-A1 | Formulations Containing an Immune Response Modifier | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-12-20 | — | — | US | disclosed |
| WO-2007071662-A1 | 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007025925-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-5190957-A | TREATMENT OF MULTI-DRUG RESISTANT TUMORS WITH QUINOLYL-AND ISOQUINOLYLOXAZOLE-2-ONES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-03-02 | — | — | US | disclosed |